Minerva Neurosciences, Inc.
NASDAQ:NERVBiotechnology
-$0.30 today
- Market cap
- $108.64M
- Beta
- -0.11
- P/E (TTM)
- -0.2
- EPS (TTM)
- -$8.46
Volume 0.28M
Average 0.21M
NERV Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Minerva Neurosciences, Inc.NASDAQ: NERV
Research & Development · Q2 FY2026 · quarter ended Jun 2026
Research & development grows, but more slowly than its trailing trend
Q2 FY2026 research & development of $7.19M rose 453.7% year over year, behind the +80515.8% change in trailing-twelve-month research & development. Sequentially, it fell 99.9% from the prior quarter. Over 3 fiscal years it compounded at -26.7% a year.
Context
- Research & development increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +453.7% toward the trailing-twelve-month pace of +80515.8%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 5.76M USD
- Year-over-year change
- -51.6%
- 4-year CAGR
- -34.9%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 5.76M | -51.6% |
| FY2024 | 2024-12-31 | 11.9M | -6.3% |
| FY2023 | 2023-12-31 | 12.71M | -13.3% |
| FY2022 | 2022-12-31 | 14.65M | -54.3% |
| FY2021 | 2021-12-31 | 32.04M | — |
Research & Development vs competitors
How NERV compares with its peers on the latest reported figures
- NERV's LTM Jun 2026 research & development of $5.27B is the highest of the 4 companies compared; the peer median is $9.2M.
- Its year-over-year change of +80515.8% is the highest of 4, against a peer median of -13.4%.
- Over three fiscal years its annual growth of -26.7% compares with a peer median of -21.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $5.27B | +80515.8% | -26.7% | — | |
| LTM Mar 2026 | $13.94M | -59.3% | -21.6% | 1624.7% | |
| LTM Dec 2025 | $9.2M | -13.4% | -21.9% | — | |
NRXSNeurAxis, Inc. | LTM Mar 2026 | $532.62K | +104.0% | +29.8% | 12.4% |
| Peer median (excluding NERV) | $9.2M | -13.4% | -21.6% | 818.6% | |
Competitors are the stored peer set for NERV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 32.04M | 14.65M | 12.71M | 11.9M | 5.76M |
| Selling, General & Admin | 13.33M | 10.58M | 10.41M | 9.95M | 9.34M |
| Operating Expenses | 45.37M | 25.23M | 23.12M | 21.85M | 15.1M |
| Depreciation & Amortization | 101.79K | 8.51K | 30.98K | 22.47K | 5.44K |
| EBITDA | (45.28M) | (24.69M) | (21.69M) | 6.02M | (293.42M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (45.37M) | (25.23M) | (23.12M) | (21.85M) | (15.1M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 16.52K | 556.95K | 1.44M | 1.27M | 948.12K |
| Interest Expense | 6.33M | 7.41M | 8.28M | 4.56M | 0 |
| Other Income / Expenses | (6.34M) | (6.88M) | (6.89M) | 23.29M | (278.32M) |
| Income Before Tax | (51.71M) | (32.11M) | (30.01M) | 1.44M | (293.42M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | (1.8M) | 0 | 0 | 0 | 0 |
| Net Income | (49.91M) | (32.11M) | (30.01M) | 1.44M | (293.42M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (9.35) | (6.01) | (4.61) | 0.19 | (34.67) |
| EPS (Diluted) | (9.35) | (6.01) | (4.61) | 0.19 | (34.67) |
| Weighted Avg Shares | 5.34M | 5.34M | 6.51M | 7.57M | 8.46M |
| Weighted Avg Shares (Diluted) | 5.34M | 5.34M | 6.51M | 7.57M | 8.46M |
Minerva Neurosciences, Inc.
NASDAQ:NERV
Intrinsic Alpha fair value
Locked
Current Price
$2.18
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.